NBRVF — Nabriva Therapeutics Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Nabriva: Rises on restructured China license deal for antibiotic
Brief: Nabriva Therapeutics And Sinovant Sciences Restructure License Agreement For Xenleta For Community-Acquired Bacterial Pneumonia In China
Brief: Nabriva Therapeutics Announces Date Of 1-For-10 Reverse Stock Split
Brief: Nabriva Therapeutics Reports Third Quarter 2020 Financial Results And Provides Corporate Updates
Brief: Nabriva's Xenleta Demonstrates High Efficacy In Patients With Community-Acquired Bacterial Pneumonia
Brief: Nabriva Therapeutics Granted New Technology Add-On Payment For Xenleta And Contepo
Brief: Nabriva Therapeutics Files For Mixed Shelf Of Upto $150 Mln
Brief: Nabriva Therapeutics Reports Q2 Financial Results
Brief: Nabriva Therapeutics Reports Second Quarter 2020 Financial Results
Brief: Nabriva Receives European Approval For XENLETA(Lefamulin) For Treatment Of Community-Acquired Pneumonia (CAP)
Brief: Nabriva Says Lefamulin Demonstrates Anti-Inflammatory Activity In Pre-Clinical Study
Brief: Nabriva Therapeutics Enters Into Exclusive Agreement To Promote And Distribute Sivextro In U.S.
Brief: WEP Clinical Partners With Nabriva Therapeutics For The Named Patient Supply Of Xenleta
Nabriva: Plunges as COVID-19 curbs thwart approval of antibiotic
FDA again declines approval of Nabriva's antibiotic for urinary tract infections
Brief: Nabriva Therapeutics Receives Complete Response Letter From FDA On NDA For Contepo For Injection
U.S. STOCKS ON THE MOVE-Pfizer, Adaptimmune, Nabriva, Beyond Meat
Nabriva Therapeutics falls on direct stock and warrants offering
Brief: Nabriva Announces $38 Mln Registered Direct Offering Priced At-The-Market Under Nasdaq Rules